Impact of LDL-cholesterol Lowering on Platelet Activation

Columbia University

Status and phase: Terminated; Phase 4

Conditions: Familial Hypercholesterolemia

Treatments: Drug: Evolocumab

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT03331666

AAAR1041

Details and patient eligibility

About

The primary goal is to assess the impact of Evolocumab therapy on platelet function of familial hypercholesterolemia (FH) patients in a randomized, double blind study. Evolocumab is a humanized monoclonal antibody that targets circulating PCSK9, increases hepatic LDL receptor, decreases plasma LDL cholesterol and reduces risk of cardiovascular events. Evolocumab (brand name Rapatha) has been approved by FDA along with diet and maximally tolerated statin therapy in adults with FH or atherosclerotic heart or blood vessel problems, who need additional lowering of LDL cholesterol.

The secondary goal is to determine if platelet activation or the response to Evolocumab therapy is modified by rs3184504 polymorphism. The investigators believe that these investigations will complement ongoing studies to demonstrate that Evolocumab reduces athero-thrombotic risk and aid the decision-making as to whether Evolocumab can reduce the atherothrombotic risk in acute coronary syndrome (ACS) patients.

Full description

Hyperlipidemia as exemplified by familial hypercholesterolemia is associated with increased platelet activation and an underlying pro-coagulant state. Hyperlipidemia primes platelets and increases platelet activation in response to various agonists. Plasma cholesterol levels appear to have a critical role in modulating platelet activity as hypercholesterolemia increases platelet activation more potently than hypertriglyceridemia. Increased platelet reactivity may contribute to the increased risk of atherothrombosis associated with hypercholesterolemia. Plasma levels of platelet activation markers such as thrombin-antithrombin complex (TAT), soluble P-selectin (sP-selectin), soluble CD40L (sCD40L) or P-selectin exposure at surface of platelets are increased in hypercholesterolemic patients. Increased levels of the platelet activation markers are associated with increased platelet membrane cholesterol content in hypercholesterolemia.Statins may show antithrombotic properties.

Enrollment: 4 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects who have a clinical diagnosis of familial hypercholesterolemia (FH)
• Subjects who are referred to Dr. Ginsberg's Lipid Practice for treatment with PCSK9 inhibitor
• Subjects with LDL cholesterol levels >100 mg/dl on baseline treatment with statins and/or ezetimibe

Exclusion criteria

• Children under 18 years of age

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

4 participants in 2 patient groups, including a placebo group

Evolocumab

Active Comparator group

Description:

Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 14 until Day 196.

Treatment:

Drug: Evolocumab

Placebo

Placebo Comparator group

Description:

Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 28 until Day 196.

Treatment:

Drug: Evolocumab